Sun damage predisposes pediatric patients to melanoma
the ONA take:
According to new research published in the Journal of Investigational Dermatology, researchers from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project have found that melanoma in some adolescent and adult patients involve many of the same genetic mutations and would likely respond to the same treatment.
For the study, researchers included 23 patients ranging in age from 9 months of 19 years old with melanoma. Researchers sequenced each person's genome and found that among the 15 patients with conventional melanoma, their tumors included various genetic mutations that were mostly consistent with ultraviolet light damage.
"We were surprised to see that so many of the pediatric melanomas had genetic changes linked to UV damage," said Richard K. Wilson, Ph.D., director of The Genome Institute at Washington University School of Medicine in St. Louis.
"This in-depth look at the genomics of pediatric melanoma is extraordinarily important for diagnosis and for selecting treatments that give young patients the best chances of a cure."
Melanoma in some adolescent and adult patients involve many of the same genetic mutations and would likely respond to the same treatment.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|